Brensocatib 10 mg + Brensocatib 25 mg + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Cystic Fibrosis Bronchiectasis
Conditions
Non-Cystic Fibrosis Bronchiectasis
Trial Timeline
Dec 1, 2020 → Oct 28, 2024
NCT ID
NCT04594369About Brensocatib 10 mg + Brensocatib 25 mg + Placebo
Brensocatib 10 mg + Brensocatib 25 mg + Placebo is a phase 3 stage product being developed by Insmed for Non-Cystic Fibrosis Bronchiectasis. The current trial status is completed. This product is registered under clinical trial identifier NCT04594369. Target conditions include Non-Cystic Fibrosis Bronchiectasis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04594369 | Phase 3 | Completed |
| NCT03218917 | Phase 2 | Completed |
Competing Products
8 competing products in Non-Cystic Fibrosis Bronchiectasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Benralizumab + Placebo to Benralizumab | AstraZeneca | Phase 3 | 77 |
| TIP + TIP and placebo + Placebo | Novartis | Phase 2 | 52 |
| CSL787 + Placebo | CSL | Phase 2 | 51 |
| HSK31858, tablet + Placebo | Haisco Pharmaceutical Group | Phase 3 | 74 |
| HSK31858 + placebo | Haisco Pharmaceutical Group | Phase 2 | 49 |
| Brensocatib 10 mg + Brensocatib 25 mg + Placebo | Insmed | Phase 2 | 49 |
| Brensocatib | Insmed | Pre-clinical | 20 |
| AP-PA02 | Armata Pharmaceuticals | Phase 2 | 44 |
Other Products from Insmed
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. + Tobramycin inhalation solution using a PARI LC® Plus nebulizer.Phase 3
74
Treprostinil Palmitil Inhalation Powder + PlaceboPhase 3
74
Treprostinil Palmitil Inhalation Powder + PlaceboPhase 3
74
ALIS + Azithromycin + Ethambutol + ELCPhase 3
74
LAI 590 mg + Multi-drug regimenPhase 3
74